<DOC>
	<DOC>NCT00445146</DOC>
	<brief_summary>The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.</brief_summary>
	<brief_title>Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Completion of a prior EVG+RTV treatment study without treatmentlimiting toxicity. Males and females of childbearing potential must agree to utilize effective contraception methods. Ability to understand and sign a written informed consent form. Females who are pregnant or breastfeeding. Participation in any other clinical trial without prior approval from the Sponsor. Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study. Subjects receiving ongoing therapy with contraindicated drugs.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Open-label</keyword>
	<keyword>Rollover</keyword>
	<keyword>Integrase Inhibitor</keyword>
	<keyword>Antiretroviral Agents</keyword>
	<keyword>Highly Active Antiretroviral Activity</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV, HIV-1, AIDS virus, Human Immunodeficiency Virus</keyword>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>treatment experienced</keyword>
</DOC>